Mr. Donal Carroll reports

FSD PHARMA SETS DATE FOR ANNUAL MEETING

FSD Pharma Inc. will hold its annual meeting of shareholders on June 29, 2021.

The meeting will address normal course matters, including the presentation of the company's audited financial statements, as well as matters contained in a requisition for a special meeting submitted to the company by certain shareholders of the company claiming to hold in excess of 5.1 per cent of the company's Class B subordinated voting shares, including two directors of the company. These shareholders are seeking to reduce the size of the company's board of directors to five and to replace six of the incumbent directors with three directors selected by such shareholders. Addressing all such matters at a single meeting will spare the shareholders of the company the additional costs and distraction that would be associated with holding two separate meetings in quick succession.

Shareholders are not required to take any action at this time in respect of the meeting. Shareholders will receive detailed information about the matters presented at the meeting in a management information circular in early June, 2021.

About FSD Pharma Inc.

FSD Pharma is a publicly traded holding company.

FSD Pharma BioSciences Inc., a wholly owned subsidiary, is a specialty biotech pharmaceutical research and development company focused on developing, over time, multiple applications of its lead compound, FSD201, by down regulating the cytokines to effectuate an anti-inflammatory response.

The company filed an investigational new drug (IND) application with the Food and Drug Administration (FDA) on Aug. 28, 2020, and was approved on Sept. 25, 2020, to initiate a phase 2 clinical trial for the use of FSD201 to treat COVID-19, the disease caused by the SARS-CoV-2 virus.

Severe COVID-19 is characterized by an overexuberant inflammatory response that may lead to a cytokine storm and, ultimately, death. The company is focused on developing FSD201 for its anti-inflammatory properties to avoid the cytokine storm associated with acute lung injury in hospitalized COVID-19 patients.

We seek Safe Harbor.